Aeon Scientific closes financing round

“We are pleased that we have been able to gain the trust of our investors. The additional funds will allow us to complete the development of our main product for clinical trials”, Dominik Bell, CEO of Aeon Scientific, says.

 

The company has previously gathered significant seed funding through various business plan competitions, Volkswirtschaftsstiftung, Venture Kick and a EU consortium project. Moreover, the development is supported by joint projects with ETH Zurich funded by the Gebert Rüf Foundation and CTI.

 

The board of directors will be strengthened with Dr. Max Link as Chairman, and Dr. Gerd Meyer. They both bring in relevant experience and network from successful careers in top management in the pharma and medtech industries.

 

Aeon Scientific develops wirelessly controlled devices to be used within the human body. As a focus the company is working on a new type of catheter steering system using its patented technology for electromagnetic manipulation. The system supports electrophysiologists during catheter ablation procedures for the treatment of arrhythmias, such as Atrial Fibrillation. It allows them to move the ablation catheter within the heart of the patient with magnetic fields. The improved control leads to better outcomes, reduced treatment costs and a higher number of patients that can be treated.